Phase 3 study for people with painful, highly inflammatory condition initiated by Galapagos 28-Apr-2023 By Liza Laws Galapagos NV has announced it has initiated a phase 3 study with small molecule drug filgotinib in patients with the chronic, highly inflammatory condition, active axial spondyloarthritis(AxSpA).
Samsung Bioepis contracts Catalent to help commercialize Benepali 19-Oct-2016 By Gareth Macdonald Samsung Bioepis has contracted Catalent to provide fill finish services for its Enbrel (etanercept) biosimilar, Benepali.